STAAR Surgical (NASDAQ:STAA – Get Free Report)‘s stock had its “equal weight” rating reiterated by research analysts at ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses ...

Staar Surgical (NASDAQ:STAA) announced the following leadership shakeup: Warren Foust has been promoted to the newly created ...

Staar Surgical (Nasdaq:STAA) announced that it made a series of changes to realign its leadership structure to better address market needs.

Piper Sandler analyst Matthew O’Brien reiterated a Hold rating on Staar Surgical (STAA – Research Report) today and set a price target of ...

Shares of Staar Surgical Co. dropped 25% on Feb. 11 after it surprised Wall Street when it reported fourth quarter sales falling 36% to $49 million.Two weeks later, the Lake Forest-based maker of ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $19.6, a high estimate of $28.00, and a low estimate of $16.00. Observing a downward trend, the current ...

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They ...

STAAR Surgical (NASDAQ:STAA – Get Free Report) rose 10.4% during trading on Tuesday .The stock traded as high as $16.90 and last traded at $16.94. Approximately 1,104,525 shares were traded ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the following ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the following ...